The effects of propranolol on blood flow through gastroesophageal collaterals and on systemic and hepatic hemodynamics were investigated in 23 cirrhotic patients with portal hypertension. Gastroesophageal collateral blood flow was evaluated by the measurement of azygos venous blood flow by continuou
Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension
✍ Scribed by Ricardo Mastai; Luis Grande; Jaime Bosch; Jordi Bruix; Joaquim Rigau; David Kravetz; Miguel Navasa; Cristobal Pera; Joan Rodés
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 507 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
The effects of pharmacological manipulation of the lower esophageal sphincter pressure on the esophageal circulation in patients with cirrhosis and portal hypertension were investigated in 33 patients by measuring the azygos venous blood flow, which is an index of blood flow through esophageal varices and periesophageal collaterals draining into the azygos venous system. Measurements were performed in baseline conditions and after the blind administration of metoclopramide (20 mg i.v.) (12 patients), domperidone (10 mg i.v.) (12 patients) and placebo (9 patients).
Both metoclopramide and domperidone caused a significant reduction of azygos blood flow, that decreased by 11.5% (p < 0.01) and 15.6% (p < 0.02) respectively, while no change was observed in patients receiving placebo (+1.4%, not statistically significant). Reduction of azygos blood flow represents a selective effect of metoclopramide and domperidone on the esophageal circulation, since portal pressure, hepatic blood flow, cardiac output, heart rate and arterial blood pressure were unchanged by the administration of metoclopramide, domperidone or placebo.
These results indicate that the administration of drugs that increase the lower esophageal sphincter pressure may reduce the inflow of blood into the esophageal varices in cirrhotic patients with portal hypertension.
Up to now, the pharmacological treatment of portal hypertension has been based on the use of vasoactive drugs that reduce pressure and blood flow within the portal venous system, such as vasopressin (l), somatostatin (2) and propranolol (3,4). A different approach may be the use of pharmacological agents that increase the lower esophageal sphincter pressure (LESP). It has been suggested (5) that the pharmacological increase of
📜 SIMILAR VOLUMES
This study investigated the correlation between changes in hepatic hemodynamics and esophageal variceal pressuremeasured with a noninvasive, pressure-sensitive endoscopic gaugein 37 portal-hypertensive cirrhotic patients receiving propranolol (0.15 mg/kg, intravenously; n = 21) or placebo (n = 16) u
The specific contribution of splenic blood inflow to portal hypertension in patients with cirrhosis is still unclear. In this study, we investigated this contribution by assessing the hemodynamic effects of transient splenic artery occlusion. In 15 cirrhotic patients, portal pressure gradient (PPG)
The pathogenesis of variceal hemorrhage is not well understood. Portal pressure and gastroesophageal collateral (azygous) blood flow are similar in patients with cirrhosis with or without a history of variceal bleeding. However, acute increases in these parameters in individual patients might predis
The effects of verapamil on hepatic and systemic hemodynamics and on liver function were investigated in 10 patients with portal hypertension due to advanced micronodular cirrhosis to verify whether, as it has been suggested, this calcium channel blocker may improve liver function and reduce portal